| Literature DB >> 28952069 |
Ge Peng1, Zhenzhen Mu1, Lixia Cui1, Pengyue Liu1, Ying Wang1, Wenqing Wu1, Xiuping Han2.
Abstract
IL-33 is a new member of the IL-1 family that plays a role in allergic disease. In this study, we evaluated the potential on the inhibition of atopic dermatitis (AD) of anti-mouse IL-33 antibody (αIL-33Ab) using 2, 4-dinitrochlorobenzene (DNCB)-induced AD mice model. We treated mice with αIL-33Ab via subcutaneous injection of each DNCB treatment 1 h later from day 1 to day 33 for 14 times. A control group received tacrolimus. Skin lesion and scratching behavior were compared. Ear thickness, dermatitis score, eosinophils and mast cells infiltration, and serum IgE levels were also analyzed. Correlations between serum IL-33 as well as soluble(s) ST2 and AD disease activity index in human AD were also investigated. DNCB-induced AD-like mice treated with αIL-33Ab showed improved AD-like symptoms. Eosinophils and mast cells infiltration and serum IgE levels were also significantly reduced by αIL-33Ab. Our study suggests that blockade of IL-33 has a curative effect on AD.Entities:
Keywords: DNCB; IL-33; atopic dermatitis; inhibition; αIL-33Ab
Mesh：
Substances：
Year: 2018 PMID： 28952069 DOI： 10.1007/s10753-017-0673-7
Source DB: PubMed Journal: Inflammation ISSN： 0360-3997 Impact factor: 4.092